Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13071053 | 0.88 | ALDH1A1 (0.46) | LGMNMAPTPOLBTP53HTT | |
| SCHEMBL12595767 | 0.85 | LMNA (0.47) | TP53MEN1KMT2AHPGDTSHR | |
| SCHEMBL12595842 | 0.82 | HRH3 (0.43) | MAPTTP53MEN1KMT2AHPGD | |
| SCHEMBL12595869 | 0.82 | HRH3 (0.42) | MEN1KMT2ALMNA | |
| SCHEMBL12595911 | 0.81 | LMNA (0.41) | MEN1KMT2ALMNA | |
| SCHEMBL12595816 | 0.80 | LMNA (0.51) | MAPTTP53ALDH1A1MEN1KMT2A | |
| SCHEMBL12595865 | 0.80 | RAD52 (0.44) | MEN1KMT2ALMNA | |
| SCHEMBL12595833 | 0.79 | LMNA (0.50) | MAPTTP53ALDH1A1MEN1KMT2A | |
| SCHEMBL12595747 | 0.79 | LMNA (0.50) | MAPTTP53ALDH1A1MEN1KMT2A | |
| SCHEMBL12595904 | 0.78 | LMNA (0.49) | TP53MEN1KMT2AHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501731-B2 | Derivatives of 6[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one having antitumor activity | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-08-06 | — | — | US | disclosed |
| US-20110112061-A1 | PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112061-A1 | PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF | PDXK, PNPO, HCCS | LGMN 3603/4885MAPT 2479/4885POLB 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.